Navigation Links
St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity
Date:5/12/2008

al ITAMs crippled a process called "negative selection." In this process, the immune system rids itself of immature T cells that might attack the body's own cells, causing autoimmune disease. Vignali said that these findings might provide insight into how autoimmune diseases start.

"One implication of our findings is that a relatively small defect in the efficiency of signal transduction through the T cell receptor could give rise to a subtle failing in negative selection, which gives rise over a long period of time to a few overly active T cells that might initiate autoimmunity," Vignali said. "Clearly from our studies there is the possibility that you don't really need a very big reduction in T cell receptor signal strength to have a defect in negative selection."

The study also showed that different T cell functions required different numbers of functional ITAMs. "We were surprised to find that many ITAMs were required to make T cells divide and expand, but only one or two was required to make T cells secrete cytokines," Vignali said. Cytokines are soluble proteins used by cells of the immune system to communicate and send messages to one another. Vignali said these basic findings represent only the beginning of more detailed studies of the role of ITAMs in T cell function.

"We believe this idea that T cell signaling acts more like a rheostat than an on/off switch offers significant new insights into how T cell development and function is controlled," Vignali said.

Other authors include Haopeng Wang, Kelly Durick Eder, Creg Workman, Kelli Boyd, Zachary Baquet, Karen Forbes and Richard Smeyne (St. Jude); Harvir Singh, Andrzej Chruscinski and Paul Utz (Stanford University School of Medicine, Stanford, Calif.); and Nicolai van Oers (The University of Texas Southwestern Medical Center, Dallas).

This work was supported by the National Institutes of Health, a Cancer Center Support CORE grant and ALSAC.

St. Jude Chil
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
2. New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR
3. New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
4. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
5. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
6. Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals
7. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
8. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
9. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
10. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
11. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2008)...S, October 2 /- Pharmaleads has obtai...authorization to perform a single,ascending dose P...,treatment of neuropathic pain., Neuropathic pain...ted,prevalence in the world,s population of up to ...y causes such as shingles, herpes, diabetes,antiv...
(Date:10/2/2008)...KHOLM, October 2 /- Athera Biotechnol...today that they have entered into a,collaboration ...r the,prevention or treatment of cardiovascular in...he recent publication of work by Athera,scientific...he Karolinska,Institutet. The research links natur...
(Date:10/2/2008)...ta Indicate Dual Modes of Action and Synergy with ...l/ -- Access Pharmaceuticals, Inc.,(OTC Bulletin B...cal,studies on Angiolix showing that by blocking l...ffect as well as a direct anti-proliferative effec...uman breast cancer (MX-1),Angiolix had a signific...
(Date:10/1/2008)...port the therapeutic potential of Amylin,s integra...sity pharmacotherapy, SAN DIEGO, Oct. 1 /PRNewswi...daq: AMLN ) today announced that new data for its...the 2008 Annual Scientific Meeting of The,Obesity ...y,s annual,meeting is one of the largest and most ...
Breaking Medicine Technology:Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Computer Aided Detection in Screening Mammography Enhances Performance of a Single Reader 11794 1Computer Aided Detection in Screening Mammography Enhances Performance of a Single Reader 11794 2Computer Aided Detection in Screening Mammography Enhances Performance of a Single Reader 11794 3Computer Aided Detection in Screening Mammography Enhances Performance of a Single Reader 11794 4The Best Way to Stoke Your Valentines Fire 3A Dont Light Up 11792 1The Best Way to Stoke Your Valentines Fire 3A Dont Light Up 11792 2Orqis 28R 29 Medicals MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meet 11789 1Orqis 28R 29 Medicals MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meet 11789 2Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings Inc to Halyard Capital LLC 11786 1Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings Inc to Halyard Capital LLC 11786 2Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings Inc to Halyard Capital LLC 11786 3
...3, 2007-- Ongoing therapeutic cancer vaccine,trial...,patient’s immune system to shrink tumors --... tend to live longer and respond,better to subsequ...cer Research, a journal of the American Associatio...nstitute researchers asks a,fundamental question: ...
...--(BUSINESS WIRE)--Jul 5, 2007 - Australian,biotec...e,completion of apricitabine,s controlled, double ...egment of its Phase IIb trial.,Patients have now p... (weeks 24 to 48) and will continue to receive 800... treatment regime.,The Company expects to release ...
Other Medicine Technology:From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 2From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 3Avexa's Apricitabine Clinical Trial Update 2
(Date:10/6/2008)... LegalView recently posted detailed infor...the potentially serious side effects caused by the...g the drug,s potential side effects are the develo...s for young adult and child patients. , ...-- LegalView, the number one resource for everythi...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rec... Garden Valley, Texas October 6, 2008 -- www.seamo...al provider of communications services to remote l...ss to the FoxNews channel via satellite to Mercy S...rica Mercy. The Africa Mercy is the world,s large...
(Date:10/6/2008)...rmany, Oct. 6 /PRNewswire-FirstCall/ -- SAP AG (NY... joined SAP as senior vice president,of the Health...ective,August 1, 2008, Mr. Papandrea will help dri...strategic software solutions to healthcare,organiz... in conjunction,with the 3rd annual Ambassadors Di...
(Date:10/5/2008)...MA...Free prescription drug samples distributed to...hysicians from Cambridge Health Alliance and Hasbr...st to look at free drug sample use among children,.... , The authors, who also serve as researchers ...dical School of Brown University, found that child...
Breaking Medicine News(10 mins):Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 2Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 3Health News:Free drug samples carry risks for children 2
..., which has already been shown to help prevent hea...r's disease and other types of dementia.// The stu...people drink - the effect is the same. Researchers...een one and three drinks a day may protect against...
...therapies results in dramatic reduction in breast ...lly powerful new approach to treating the conditio...were found to work synergistically to inhibit the ... receptors, HER2 and epidermal growth factor recep...
...ration, production and marketing rights of the ant...echnology in the Jawaharlal Nehru University (JNU)...market in 3-4 months. The Company has made a miles...addition, it will pay the university a royalty on ...
...laboured under the assumption that the influenza v... its structure and carry out its activities. Howev...a new, “hidden” influenza virus protein.This prote...rus, thereby contributing to the virus’s potency, ...
Other Medicine News:
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Medicine Products: